Archive
All News
Every briefing, headline, and filing we've published, newest first.
PipelinePharmaVoice ↗
The protein is implicated in a wide swath of cancers, but harnessing it for drug R&D is still a major scie…
Amgen paid $28.3 billion for Horizon Therapeutics in 2023. Three Phase 3 readouts over the next 18 months deci…
PolicyKFF Health News ↗
This brief highlights lessons from “Medicaid unwinding" that could help inform work requirement implementation…
MoneyPharmaVoice ↗
Several of pharma’s top leaders scored large pay bumps last year, including two new chiefs who joined th…
PipelinePharmaVoice ↗
Roche, AstraZeneca and Sanofi demonstrate how companies are following their own R&D paths.…
The WeekDrug Channels ↗
Informa Connect’s Life Sciences Pricing & Contracting USA May 18-20, 2026 | Philadelphia, PA Drug Channels rea…
PolicyKFF Health News ↗
This tracker examines Executive Actions taken by the Trump administration that have the potential to impact LG…
PolicyKFF Health News ↗
This brief provides on overview of funding proposals for domestic HIV programs and initiatives in President Tr…
MoneyPharmaVoice ↗
Biotech IPOs gain long-lost momentum, and pharma companies find a way around the White House’s harsh tar…
PolicyPharmaVoice ↗
With competition fierce in the weight loss space, a potential change to how the FDA classifies peptides could …
NegotiationsDrug Channels ↗
This week, I’m rerunning some popular posts while we prepare for today’s live video webinar: PBM Industry Upda…
PolicyKFF Health News ↗
False claims about the safety of mifepristone are driving legislative and investigative action in Congress, ev…
PipelinePharmaVoice ↗
Dr. Ebrahim Delpassand, founder and CEO of RadioMedix, played a pivotal role in advancing nuclear medicine as …
NegotiationsDrug Channels ↗
This week, I’m rerunning some popular posts while we prepare for Friday’s live video webinar: PBM Industry Upd…
PolicyDrug Channels ↗
This week, I’m rerunning some popular posts while we prepare for Friday’s live video webinar: PBM Industry Upd…
The WeekDrug Channels ↗
Today’s guest post comes from Chrissy Hand, Chief Product and Commercial Officer at CoverMyMeds. Chrissy highl…
The WeekDrug Channels ↗
Spring is here in always-sunny Philadelphia. The vernal equinox has brought us an unexpected bounty of notewor…
DataDrug Channels ↗
Three is still the magic number for pharmacy benefit managers (PBMs). For 2025, 80% of all equivalent prescrip…
AbbVie's $5.9B JAK1 inhibitor is the next Humira — and the biosimilar pipeline is already forming seven years …
The WeekDrug Channels ↗
We had an absolutely incredible time at the second annual Drug Channels Leadership Forum (DCLF)! Despite some …
The list price grabs the headline. The cost of care is closer to $3M — and Medicaid is on the hook for most of…
← Newer
Page 17
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.